Orexigen expects 2nd half Contrave resubmission; Arena seeks European, Chinese partners
This article was originally published in Scrip
Executive Summary
If all goes well, Orexigen Therapeutics could resubmit its new drug application (NDA) for its antiobesity medicine Contrave (naltrexone SR/bupropion SR) to the US FDA in the second half of this year, with the potential the firm could finally gain approval of the drug in early 2014, the company said on 7 January, noting those plans depend on the timing of an interim analysis of its cardiovascular outcomes trial (CVOT).